Tempus AI (NASDAQ:TEM) Trading Down 1.4% - Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price fell 1.4% on Tuesday . The stock traded as low as $58.35 and last traded at $58.16. 6,469,384 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 13,663,560 shares. The stock had previously closed at $59.00.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. TD Cowen reiterated a "buy" rating and set a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Guggenheim reissued a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Wolfe Research cut shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Needham & Company LLC upped their target price on shares of Tempus AI from $56.00 to $70.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Finally, William Blair reiterated a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Tempus AI has an average rating of "Moderate Buy" and an average target price of $61.18.

Tempus AI Trading Down 8.6 %

The stock's fifty day moving average price is $58.13 and its 200 day moving average price is $51.48. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Remove Ads

Insiders Place Their Bets

In related news, major shareholder Bradley A. Keywell sold 170,720 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total transaction of $6,052,024.00. Following the completion of the sale, the insider now owns 15,993,729 shares in the company, valued at approximately $566,977,693.05. This represents a 1.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nadja West sold 809 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total transaction of $41,347.99. Following the completion of the transaction, the director now directly owns 37,705 shares in the company, valued at approximately $1,927,102.55. The trade was a 2.10 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,598,969 shares of company stock worth $317,194,162.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TEM. Operose Advisors LLC bought a new stake in Tempus AI during the 4th quarter worth approximately $25,000. Farther Finance Advisors LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at about $34,000. Prestige Wealth Management Group LLC boosted its stake in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after acquiring an additional 965 shares during the period. NewEdge Advisors LLC purchased a new stake in shares of Tempus AI during the fourth quarter worth about $49,000. Finally, First Horizon Advisors Inc. raised its stake in Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock valued at $55,000 after purchasing an additional 1,108 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.